← Leaderboards
Carlos E. Mendoza-Santiesteban
Iscreen 2 Prevent Llc
$179,161
Attributed
$520,890
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $461.2K · FY2021–22$500K$375K$250K$125K$0
'21
'22
Funding mix
By agency
NIH$520,890 · 1
By mechanism
R41$520,890 · 1
Top collaborators
- Delia Cabrera-Debuc3 shared
- Alberto Rafael Ramos2 shared
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposCostImpaired CognitionScreeningRetinaBiological MarkersMild Cognitive ImpairmentMethodologyProtective FactorsRisk FactorsVisualUnited StatesDiagnostic TechnologiesBrainS DiseaseHealthcareCognitiveInstrumentDementiaDiscriminationAmericanBiophysicsDiagnosisDiagnostic
Grant awards (3)
An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease$33,187
R41 · FY2022 · AG
An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease$26,488
R41 · FY2022 · AG
An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease$461,215
R41 · FY2021 · AG